Physician profile
Matthew Mah
NPI 1730686130
$2,606.07
in general payments reported to CMS, 2019-2025
12 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,762 · 2022: $284 · 2023: $40.30 · 2024: $119 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,093.38 | 2021-2025 | Ortholoc 2 Lapifuse, Augment Injectable, Fuseforce |
| Anika Therapeutics, INC. | $869.86 | 2021 | |
| Organogenesis INC. | $413.11 | 2021-2025 | Puraply Wound Matrix, Simplimax |
| Averitas Pharma INC. | $51.45 | 2023-2024 | Qutenza |
| Alfasigma USA, INC. | $33.96 | 2022 | |
| Treace Medical Concepts, INC. | $31.16 | 2022 | |
| Orthofix Medical, INC. | $25.04 | 2025 | Physio-Stim |
| Azurity Pharmaceuticals, INC. | $24.51 | 2022-2023 | Horizant |
| Integra Lifesciences Corporation | $18.96 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Bioventus LLC | $17.36 | 2022 | |
| Hartmann USA, INC. | $13.96 | 2022 | |
| Biotissue Holdings INC. | $13.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.